Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 15/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ATM | Q13315 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292767 | 0.87 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4283881 | 0.84 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL1180783 | 0.84 | CYP19A1 (0.76) | SREBF2CYP19A1MAPTATMALDH1A1 | |
| SCHEMBL4281169 | 0.84 | SREBF2 (1.00) | SREBF2CYP19A1MAPTATML3MBTL1 | |
| SCHEMBL4293667 | 0.83 | SREBF2 (0.69) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4279415 | 0.80 | SREBF2 (1.00) | SREBF2CYP19A1MAPTATML3MBTL1 | |
| Fatostatin SCHEMBL2742732 | 0.78 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| Fatostatin SCHEMBL29458338 | 0.78 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL19758233 | 0.78 | SREBF2 (0.90) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL12844174 | 0.78 | SREBF2 (0.63) | SREBF2CYP19A1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | claimed |
| US-8927578-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-06 | — | — | US | claimed |
| US-8778976-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2014-07-15 | — | — | US | claimed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | claimed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | claimed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | claimed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | claimed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | claimed |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2018-10-11 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | SREBF2 1767/4885CYP19A1 1216/4885MAPT 4275/4885 |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | FABP4, LIPC, PNLIP | SREBF2 17/4885CYP19A1 178/4885MAPT 3356/4885 |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885CYP19A1 186/4885MAPT 3510/4885 |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885CYP19A1 186/4885MAPT 3510/4885 |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 31/4885CYP19A1 186/4885MAPT 3510/4885 |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | SREBF2 32/4885CYP19A1 185/4885MAPT 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.